2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 557 | 33.122 | 119.550 | - | 207.013 | 243.625 | 245.852 | 223.456 | 246.355 | 281.108 |
Total Income - EUR | 557 | 33.122 | 119.550 | - | 207.013 | 243.625 | 245.852 | 223.456 | 246.355 | 281.108 |
Total Expenses - EUR | 1.054 | 22.603 | 104.887 | - | 187.219 | 227.233 | 237.923 | 211.688 | 226.170 | 256.824 |
Gross Profit/Loss - EUR | -496 | 10.519 | 14.663 | - | 19.795 | 16.393 | 7.929 | 11.768 | 20.185 | 24.283 |
Net Profit/Loss - EUR | -513 | 9.525 | 12.738 | - | 17.709 | 13.956 | 5.463 | 9.533 | 17.722 | 21.472 |
Employees | 0 | 1 | 4 | - | 4 | 7 | 8 | 8 | 6 | 6 |
Check the financial reports for the company - Apoteka Irispharm Srl
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 1.205 | 1.215 | 5.828 | - | 12.395 | 21.373 | 20.968 | 15.449 | 10.427 | 7.363 |
Current Assets | 4.975 | 13.726 | 35.724 | - | 81.786 | 90.574 | 94.199 | 111.091 | 95.799 | 114.780 |
Inventories | 4.038 | 6.647 | 19.613 | - | 21.975 | 67.435 | 43.027 | 44.053 | 45.420 | 60.613 |
Receivables | 738 | 2.431 | 4.936 | - | 27.071 | 21.050 | 29.794 | 32.566 | 42.454 | 44.936 |
Cash | 199 | 4.647 | 11.175 | - | 32.739 | 2.089 | 21.378 | 34.472 | 7.926 | 9.230 |
Shareholders Funds | -468 | 9.052 | 21.698 | - | 54.895 | 67.998 | 72.173 | 80.105 | 48.517 | 69.719 |
Social Capital | 45 | 45 | 45 | - | 43 | 253 | 248 | 243 | 243 | 243 |
Debts | 6.648 | 5.888 | 19.855 | - | 39.286 | 43.949 | 42.994 | 46.435 | 57.709 | 52.424 |
Income in Advance | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "4773 - 4773" | |||||||||
CAEN Financial Year |
4773
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Apoteka Irispharm Srl